Lyon, France, June 2, 2022 – 6:00 p.m. CEST – MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotechnology company pioneering the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving the survival of cancer patients, announces today the completion of its CIMON Phase 1b trial evaluating the safety and tolerance of MaaT033, its high microbial richness and diversity MET for oral administration, in patients with acute myeloid leukemia ( LAM) or high-risk myelodysplastic syndrome who received intensive chemotherapy. In this study carried out in immuno-compromised patients, MaaT033 presented a good safety and tolerance profile (primary endpoint).